Related Experiment Video
Updated: Mar 1, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with
Insights
Ibrutinib significantly improves progression-free survival for patients with relapsed/refractory chronic lymphocytic leukemia (CLL), even those with high-risk genetic mutations. Updated RESONATE trial data confirm ibrutinib
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Chronic lymphocytic leukemia (CLL) is often treated with chemotherapy, but relapsed/refractory cases with high-risk genetic factors present challenges.
- Ibrutinib has emerged as a targeted therapy option for CLL patients.
- The RESONATE trial previously demonstrated ibrutinib's superiority over ofatumumab in this population.
Purpose of the Study:
- To report updated efficacy and safety findings from the phase 3 RESONATE study.
- To evaluate ibrutinib's performance in specific high-risk genomic subgroups of relapsed/refractory CLL.
- To assess the impact of genetic mutations on treatment outcomes.
Main Methods:
- Updated analysis of the phase 3 RESONATE study data.
- Median follow-up of 19 months.
- Genomic mutations identified using the Foundation One Heme Panel.
Main Results:
- Ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) compared to ofatumumab.
- At 24 months, 74% of ibrutinib-treated patients remained alive and progression-free.
- Efficacy was consistent across prognostic subgroups, including del17p and del11q.
- Patients with both TP53 mutation and del17p showed reduced PFS within the ibrutinib arm.
- Ibrutinib showed better PFS in second-line therapy compared to later lines.
Conclusions:
- Ibrutinib offers robust clinical activity and acceptable safety in relapsed/refractory CLL with high-risk mutations.
- Treatment outcomes with ibrutinib are largely independent of common high-risk genetic abnormalities.
- Updated RESONATE data reinforce ibrutinib's role in managing challenging CLL cases.
Abstract:
In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic factors. We report updated results from RESONATE in these traditionally chemotherapy resistant high-risk genomic subgroups at a median follow-up of 19 months. Mutations were detected by Foundation One Heme Panel. Baseline mutations in the ibrutinib arm included TP53 (51%), SF3B1 (31%), NOTCH1 (28%), ATM (19%) and BIRC3 (14%). Median PFS was not reached, with 74% of patients randomized to ibrutinib alive and progression-free at 24 months. The improved efficacy of ibrutinib vs ofatumumab continues in all prognostic subgroups including del17p and del11q. No significant difference within the ibrutinib arm was observed for PFS across most genomic subtypes, although a subset carrying both TP53 mutation and del17p had reduced PFS compared with patients with neither abnormality. Reduced PFS or OS was not evident in patients with only del17p. PFS was significantly better for ibrutinib-treated patients in second-line vs later lines of therapy. The robust clinical activity of ibrutinib continues to show ongoing efficacy and acceptable safety consistent with prior reports, independent of various known high-risk mutations.
